Taking Psychiatric Meds Is Way More Common Than You Think

Even though there’s been a lot of buzz about destigmatizing mental health issues lately-everyone from Demi Lovato to Selena Gomez has been open about their ongoing struggles-we still have a long way to go in terms of normalizing seeking help for mental disorders. That’s why we were interested to see new research that appeared earlier this month in JAMA Internal Medicine , which examined exactly how many people in the United States are taking antidepressants, anxiety meds, and anti-psychotic medications.

Researchers Develop First Chikungunya Vaccine From Benign Insect-Specific Virus

Researchers from the University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn’t have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungunya virus.

Increased Cases Of Respiratory Illness In Barbados

The Ministry of Health in a statement did not give figures to indicate the number of cases, but noted that “for the subset of cases tested, the causative organism was not the flu virus but mostly Respiratory Syncytial Virus . “Nevertheless, PAHO has advised that the incidence of seasonal flu is starting to increase in North America and sporadic cases are also being seen in neighbouring islands.”

GOP Says It Plans to Replace Obamacare With “Universal Access”

Responding to criticism that repealing the Patient Protection and Affordable Care Act would leave millions without health insurance, House Republicans have announced that their goal in replacing the PPACA is to guarantee “universal access” to health care and coverage, not necessarily to ensure that everyone has insurance, according to an article in The New York Times. “Our goal here is to make sure that everybody can buy coverage or find coverage if they choose to,” a House leadership aide told journalists.

FDA Drops Boxed Warning From Chantix Label

… be observed for the occurrence of such symptoms and should be instructed to discontinue varenicline and contact a health care provider if they experience such symptoms. The E valuating A dverse Events in a GL obal Smoking C E ssation S tudy (EAGLES) …

ContraVir expands mid-stage study of tenofovir prodrug analog into higher dose

ContraVir Pharmaceuticals broadens its ongoing Phase 2a study evaluating tenofovir exalidex against Gilead Sciences’ tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection by increasing the highest planned dose to 150 mg/day from 100 mg/day. The 84-subject sequential dose escalation study is assessing once-daily doses of TXL for four weeks against 300 mg of TDF once daily.

Therapy Focus – Immunotherapy Closes In On Triple-Negative Tumors

Celgene admitted as much last week by saying it would not push a promising Abraxane-containing chemotherapy regimen into pivotal trials in this Several studies are already under way, most notably a large first-line phase III trial of Abraxane plus Roche’s anti-PD-L1 antibody Tecentriq. Early data are encouraging, and hopes are high that meaningful survival benefits will emerge in the next couple of years.

What is Fluimucil and why would Wiggins need it?

In Monday’s hearing in front of the Culture, Media and Sport Committee, Team Sky principal Dave Brailsford at last revealed the contents of a package that was delivered to the team at the 2011 Criterium du Dauphine. Brailsford said: “Doctor Freeman told me that it was Fluimucil that was in the package, a product that is for a nebuliser.”

Woman is first to have baby after ovaries frozen as a child

A 24-year-old Dubai native has become the first woman to give birth after having her fertility restored from ovarian tissue frozen during her childhood. She is the first person in the world to have had a successful pregnancy using ovarian tissue that was harvested before the onset of puberty and the only person to have her ovaries transplanted back after 13 years in storage.

Advertisers and crib manufacturers fail to adhere to safe sleep recommendations for infants

A new study from the University of Alabama at Birmingham shows that national magazine advertisements and manufacturers of infant cribs continue to depict unsafe sleep environments, despite longtime guidelines established by the American Academy of Pediatrics to protect against SIDS and other sleep-related deaths. “It is important that health care providers, advertisers and crib manufacturers come together to educate parents and caregivers about safe sleep environments for children,” said Bradley Troxler, M.D., assistant professor and director of the UAB Pediatric Pulmonary Center who treats patients at Children’s of Alabama.

DPP IV Inhibitors

… Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market………….. II-5 Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 …

Press release distribution, EDGAR filing, XBRL, regulatory filings

Pfizer Receives Approval in the European Union for Nimenrix in Infants Six Weeks of Age and Older )–Pfizer Inc. announced today the European Commission has approved an expanded indication for Nimenrixa Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express High Levels of PD-L1 )–KEYTRUDA Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express H… )–Madame Tussauds and country superstar Brad Paisley joined forces to pay tribute to Grand Ole Opry legend Little Jimmy Dickens by unveiling his wax figure on the R… )–Manitowoc Foodservice announces SVP, General Counsel and Secretary Maurice Jones retirement; promotes Joel Horn to SVP, General Counsel and Secretary effecti… )–Mitsubishi UFJ Capital, a … (more)

Home buyer plan short-term gain for long-term pain

Premier Christy Clark’s home-buyers plan is short-term gain for the B.C. Liberal Party and long-term pain for both those who borrow money from the government, taxpayers and the entire B.C. housing market . But for Clark this is all about getting re-elected next May. Who cares if some first-time home buyers can’t make their mortgage payments and lose their houses down the road? What’s it to her if housing prices go up for everyone because the B.C. government plan will reduce already limited supply? As flimflams go, this one is impressively slippery and a lucrative Christmas present to the B.C. Liberals’ biggest donors the real estate industry .

Elder Cosmetic Surgery

… she spent the insurance money on it. She said she wanted to look good.” That’s one thing about plastic surgery – health care insurance does not pay. It’s a cash-only business with prices as high as the traffic will bear. Another thing about plastic …

Hepatitis C is commonly spread by sharing needles and can hide for years without producing symptoms

HEPATITIS C remains a ‘major public health problem’ in the North West with more than 1,400 people infected in Bolton. According to Public Health England’s latest figures, it is estimated that 2,063 people in Bolton have been infected with Hep C. A proportion clear the infection themselves but the latest figures, collated in 2014, show 1,423 still had the infection and 388 received treatment.

Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424

Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company’s new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.

Catalyst Biosciences Completes Manufacturing Agreements for its Novel …

Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced it has secured all rights to the manufacturing process for marzeptacog alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors.

This drugmaker is taking an unprecedented approach to getting its cancer treatment approved

As researchers look for new approaches for tough-to-treat cancer, many are looking into genetics – more specifically, they’re looking at the type of genetic mutations found in cancerous tumors. One company in particular, called Loxo Oncology is building drugs that act on those mutations, so that the type of cancer someone has wouldn’t matter so much as the genetic information gleaned from sequencing the tumor.

WebMD Predicts Cold and Flu Symptoms to Rise During the Holidays

Visitors can see a county-by-county breakdown of the cities currently impacted by cold and flu symptoms, as well as those cities expected to see an increase in the weeks ahead, on the WebMD Cold and Flu Interactive Map. According to the WebMD Cold and Flu Map, the top five cities anticipated to experience the highest levels of cold and flu symptoms are Sponsored by RB, a leading consumer health and hygiene company, the WebMD Cold and Flu interactive map leverages various data sources, including millions of WebMD Symptom Checker checks per month, to present a real-time analysis of the spread of cold and flu so that consumers can take preventative measures to keep themselves and their families healthy during the holidays.

Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline

Tetraphase Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, today provided a regulatory and clinical development update for eravacycline, the Company’s lead antibiotic candidate with potent activity against MDR pathogens, which is being developed for the treatment of serious and life-threatening bacterial infections. During the second half of 2017, Tetraphase plans to submit a Marketing Authorization Application to the European Medicines Agency for IV eravacycline for the treatment of cIAI.